Abstract
We are frankly disappointed by the recent article by Holmes et al. 1 appraising the risk of death in patients randomized to sirolimus-eluting (Cypher) vs. bare-metal stents, which amounts to a missed opportunity. Indeed, analysis and reporting are clearly inadequate to provide a reliable answer to the scientific question posed. First, given the focus on randomized trials with sirolimus-eluting vs. bare-metal stents and the likely endorsement by Cordis (manufacturer of Cypher), it is unclear why other potentially eligible trials were not included (e.g. the SES-SMART or the DIABETES studies). This type of methodological error, potential harbinger of publication bias, is well known to authors and readers of systematic reviews …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
